2020Cancer UrologyOpen access

Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case

Andrey Meshcheryakov, О. О. Гордеева

Open full text 0 citations

Abstract

Nowadays there are several effective drugs to treat castration-resistant prostate cancer. However, treatment options are still limited. In this regard, overcoming the resistance to the prescribed treatment remains extremely important. One possible way is to replace prednisone with dexamethasone when using abiraterone acetate. There are several studies, including randomized ones, which confirm the rationality of this method. We present a literature review and our own clinical observation, which demonstrates the possibility of repeated long-term (3 years) use of abiraterone acetate after replacing a steroid drug in an intensively pre-treated patient with castration-resistant prostate cancer.

Open-access reader

About this research paper

What this paper is about

Nowadays there are several effective drugs to treat castration-resistant prostate cancer. However, treatment options are still limited. In this regard, overcoming the resistance to the prescribed treatment remains extremely important. One possible way is to replace prednisone with dexamethasone when using abiraterone acetate. There are several studies, including randomized ones, which confirm the rationality of this method. We present a literature review and our own clinical observation, which demonstrates the possibility of repeated long-term (3 years) use of abiraterone acetate after replacing a steroid drug in an intensively pre-treated patient with castration-resistant prostate cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Nowadays there are several effective drugs to treat castration-resistant prostate cancer. However, treatment options are still limited. In this regard, overcoming the resistance to the prescribed treatment remains extremely important. One possible way is to replace prednisone with dexamethasone when using abiraterone acetate. There are several studies, including randomized ones, which confirm the rationality of this method. We present a literature review and our own clinical observation, which demonstrates the possibility of repeated long-term (3 years) use of abiraterone acetate after replacing a steroid drug in an intensively pre-treated patient with castration-resistant prostate cancer.

Key concepts: Abiraterone acetate, Medicine, Prostate cancer, Abiraterone, Prednisone, Cabazitaxel, Castration, Dexamethasone

Related papers

Back to paper searchBrowse research topicsOriginal source
Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case — Research Paper | ScholarLens